John L Higgins - Net Worth and Insider Trading

John L Higgins Net Worth

The estimated net worth of John L Higgins is at least $61 Million dollars as of 2024-11-05. John L Higgins is the Director of Ligand Pharmaceuticals Inc and owns about 422,984 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $47 Million. John L Higgins is the Director of OmniAb Inc and owns about 2,462,686 shares of OmniAb Inc (OABI) stock worth over $11 Million. John L Higgins is also the Director of Bio-Techne Corp and owns about 36,608 shares of Bio-Techne Corp (TECH) stock worth over $3 Million. Details can be seen in John L Higgins's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John L Higgins has not made any transactions after 2024-05-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of John L Higgins

To

John L Higgins Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John L Higgins owns 5 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Bio-Techne Corp (TECH) , and BioCryst Pharmaceuticals Inc (BCRX) among others .

Click here to see the complete history of John L Higgins’s form 4 insider trades.

Insider Ownership Summary of John L Higgins

Ticker Comapny Transaction Date Type of Owner
LGND Ligand Pharmaceuticals Inc 2022-12-16 CEO & President
TECH Bio-Techne Corp 2024-05-14 director
BCRX BioCryst Pharmaceuticals Inc 2005-05-11 director
LIMIT LIMIT 2022-11-01 director
LIMIT LIMIT 2023-05-23 director

John L Higgins Latest Holdings Summary

John L Higgins currently owns a total of 3 stocks. Among these stocks, John L Higgins owns 422,984 shares of Ligand Pharmaceuticals Inc (LGND) as of December 16, 2022, with a value of $47 Million and a weighting of 77.41%. John L Higgins owns 2,462,686 shares of OmniAb Inc (OABI) as of May 23, 2023, with a value of $11 Million and a weighting of 17.96%. John L Higgins also owns 36,608 shares of Bio-Techne Corp (TECH) as of May 14, 2024, with a value of $3 Million and a weighting of 4.63%.

Latest Holdings of John L Higgins

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
LGND Ligand Pharmaceuticals Inc 2022-12-16 422,984 111.28 47,069,660
OABI OmniAb Inc 2023-05-23 2,462,686 4.44 10,922,012
TECH Bio-Techne Corp 2024-05-14 36,608 76.92 2,815,704

Holding Weightings of John L Higgins


John L Higgins Form 4 Trading Tracker

According to the SEC Form 4 filings, John L Higgins has made a total of 7 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years, including 0 buys and 7 sells. The most-recent trade in Ligand Pharmaceuticals Inc is the sale of 10,000 shares on December 16, 2022, which brought John L Higgins around $618,700.

According to the SEC Form 4 filings, John L Higgins has made a total of 3 transactions in OmniAb Inc (OABI) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in OmniAb Inc is the sale of 9,000 shares on May 23, 2023, which brought John L Higgins around $36,450.

According to the SEC Form 4 filings, John L Higgins has made a total of 5 transactions in Bio-Techne Corp (TECH) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Bio-Techne Corp is the sale of 4,000 shares on May 14, 2024, which brought John L Higgins around $335,360.

Insider Trading History of John L Higgins

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John L Higgins Trading Performance

GuruFocus tracks the stock performance after each of John L Higgins's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John L Higgins is 3.88%. GuruFocus also compares John L Higgins's trading performance to market benchmark return within the same time period. The performance of stocks bought by John L Higgins within 3 months outperforms 4 times out of 11 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John L Higgins's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John L Higgins

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
6 out of 11 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 3.1 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 0.96 LIMIT LIMIT LIMIT LIMIT LIMIT

John L Higgins Ownership Network

Ownership Network List of John L Higgins

No Data

Ownership Network Relation of John L Higgins

Insider Network Chart

John L Higgins Owned Company Details

What does Ligand Pharmaceuticals Inc do?

Who are the key executives at Ligand Pharmaceuticals Inc?

John L Higgins is the CEO & President of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include CHIEF LEGAL OFFICER & Andrew Reardon , VP & Finance and CFO Matthew E Korenberg , and Chief Financial Officer Octavio Espinoza .

Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary

Over the past 18 months, John L Higgins made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 70,748 shares made by Matthew E Korenberg , a net sale of 14,708 shares made by Octavio Espinoza , and a net sale of 13,500 shares made by Andrew Reardon .

In summary, during the past 3 months, insiders sold 57,925 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 2,500 shares, with a net sale of 55,425 shares. During the past 18 months, 119,043 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 6,500 shares were bought by its insiders, resulting in a net sale of 112,543 shares.

Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Ligand Pharmaceuticals Inc Insider Transactions

No Available Data

John L Higgins Mailing Address

Above is the net worth, insider trading, and ownership report for John L Higgins. You might contact John L Higgins via mailing address: 11119 North Torrey Pines Road, Suite 200, La Jolla Ca 92037.